Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia ; volume:13 ; number:1 ; day:16 ; month:11 ; year:2013 ; pages:1-9 ; date:12.2013
BMC cancer ; 13, Heft 1 (16.11.2013), 1-9, 12.2013
- Urheber
-
Kamioner, Didier
- Beteiligte Personen und Organisationen
-
Fruehauf, Stefan
Maloisel, Fréderic
Cals, Laurent
Lepretre, Stéphane
Berthou, Christian
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-13-547
- URN
-
urn:nbn:de:1111-2016030411729
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kamioner, Didier
- Fruehauf, Stefan
- Maloisel, Fréderic
- Cals, Laurent
- Lepretre, Stéphane
- Berthou, Christian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients (Review)
Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients (Review)
Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients (Review)
Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US